453562-71-5

Basic information

• Product Name: 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDRO-INDOLE
• Synonyms: 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDRO-INDOLE;1-(6-amino-3,3-dimethylindolin-1-yl)ethanone;1-(6-amino-3,3-dimethylin...;1-Acetyl-6-amino-2,3-dihydro-3,3-dimethyl-1H-indole, 1-(6-Amino-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl)ethan-1-one;1-Acetyl-6-amino-3,3-dimethylindoline;1-(6-aMino-3,3-diMethyl-2,3-dihydro-indol-1-yl)-ethanone;1-(6-amino-3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)ethan-1-one;1H-Indol-6-amine, 1-acetyl-2,3-dihydro-3,3-dimethyl-
• CAS NO: 453562-71-5
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 204.27
• Mol File: 453562-71-5.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 429.848ºC at 760 mmHg
• Flash Point: 213.765ºC
• Appearance: /
• Density: 1.125g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDRO-INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDRO-INDOLE(453562-71-5)
• EPA Substance Registry System: 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDRO-INDOLE(453562-71-5)

Safety Data

• Hazardous Substances Data: 453562-71-5(Hazardous Substances Data)

Usage

General Description

1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDRO-INDOLE, also known as 6-AADMI, is a chemical compound with potential anti-inflammatory and antinociceptive properties. It is a derivative of indole, a heterocyclic aromatic organic compound, and is characterized by the presence of an acetyl group and an amino group on the indole ring. 6-AADMI has been studied for its potential therapeutic applications in the treatment of inflammatory disorders and pain management. Its mechanism of action involves modulation of pro-inflammatory cytokines and proteins that contribute to pain signaling, making it a promising candidate for the development of new drugs for these conditions. Further research is needed to fully understand its pharmacological properties and potential uses in clinical settings.

InChI:InChI=1/C12H16N2O/c1-8(15)14-7-12(2,3)10-5-4-9(13)6-11(10)14/h4-6H,7,13H2,1-3H3

Upstream product

• 90221-50-4 N-(2-bromo-5-nitrophenyl)acetamide 
• 10403-47-1 2-bromo 5-nitroaniline 
• 453562-67-9 N-(2-bromo-5-nitrophenyl)-N-(2-methylprop-2-enyl)-acetamide 
• 453562-68-0 1-(3,3-dimethyl-6-nitro-2,3-dihydro-indol-1-yl)-ethanone 

Downstream Products

• 871107-54-9 1-(6-(7-(3-Chloropyridin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ylamino)-3,3-dimethylindolin-1-yl)ethanone 
• 659731-42-7 1-(6-iodo-3,3-dimethylindolin-1-yl)ethanone 
• 645418-60-6 N-(1-acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-amino-benzamide 
• 914611-07-7 1-{6-[6-(3-chloro-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-3,3-dimethyl-2,3-dihydro-indol-1-yl}-ethanone 
• 1202764-91-7 6-iodo-3,3-dimethyl-2,3-dihydro-1H-indole hydrochloride 
• 1158751-97-3 6-iodo-3,3-dimethylindoline 
• 1259511-94-8 4-(3,3-dimethylindolin-6-yl)morpholine 
• 1259512-37-2 4-(1-(7-fluoro-3-methyl-2-(2-pyridinyl)-4-quinolinyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-6-methyl-2-pyrimidinamine 
• 1259512-13-4 4-(1-(7-fluoro-3-methyl-2-(2-pyridinyl)-4-quinolinyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-pyrimidinamine 
• 1259513-38-6 4-(3,3-dimethyl-6-(4-pyridinyl)-2,3-dihydro-1H-indol-1-yl)-7-fluoro-3-methyl-2-(2-pyridinyl)quinoline 
• 1259512-15-6 4-(3,3-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indolin-1-yl)-7-fluoro-3-methyl-2-(pyridin-2-yl)quinoline 
• 1259512-14-5 7-fluoro-4-(6-iodo-3,3-dimethylindolin-1-yl)-3-methyl-2-(pyridin-2-yl)quinoline 
• 1259513-39-7 3,3-dimethyl-6-(pyridin-4-yl)indoline 
• 1259511-98-2 4-(3,3-dimethyl-6-(4-morpholinyl)-2,3-dihydro-1H-indol-1-yl)-7-fluoro-3-methyl-2-(3-pyridinyl)quinoline 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.